Travere director sells 8,000 shares after option exercise
Travere Therapeutics director Jeffrey A. Meckler exercised stock options for 8,000 shares of common stock at $16.33 per share, then sold 8,000 shares at $45.00 per share in an open‑market transaction.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Travere Therapeutics director Jeffrey A. Meckler exercised stock options for 8,000 shares of common stock at $16.33 per share, then sold 8,000 shares at $45.00 per share in an open‑market transaction. The sale was made under a pre‑arranged Rule 10b5‑1(c) trading plan. Following these transactions, Meckler directly owns 87,500 shares of Travere Therapeutics common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,000 shares ($229K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Meckler Jeffrey A
Role
Director
Sold
8,000 shs ($360K)
Approx. gross sale proceeds
$360K
Approx. exercise cost
$131K
Approx. pre-tax spread
$229K
Share of Position Sold
8.4%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 8,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,000 | $16.33 | $131K |
| Sale | Common Stock | 8,000 | $45.00 | $360K |
Holdings After Transaction:
Stock option (right to buy) — 0 options (Direct);
Common Stock — 87,500 shares (Direct)
Holdings Before and After:
Stock option (right to buy), 8,000 to 0 options (Direct);
Common Stock, 87,500 to 87,500 shares (Direct)
Other Insiders: 9 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (2)
- F1. This sale was made pursuant to a written plan adopted on November 17, 2025 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on May 18, 2016 with an expiration date of May 18, 2026.
- F2. The stock option is fully vested and exercisable.
Key Figures
Shares sold: 8,000 shares
Sale price: $45.00 per share
Shares exercised: 8,000 shares
+3 more
6 metrics
Shares sold
8,000 shares
Common stock sold on May 4, 2026 at $45.00
Sale price
$45.00 per share
Open-market sale of 8,000 common shares
Shares exercised
8,000 shares
Stock option exercise into common stock on May 4, 2026
Option exercise price
$16.33 per share
Exercise price of stock option granted May 18, 2016
Shares held after
87,500 shares
Direct common stock ownership after transactions
Option expiration
May 18, 2026
Expiration date of exercised stock option
Key Terms
Rule 10b5-1(c), stock option, open-market sale, derivative security
4 terms
Rule 10b5-1(c) regulatory
"written plan adopted on November 17, 2025 meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
stock option financial
"consists of the sale of shares underlying a stock option granted to the Reporting Person"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Travere Therapeutics (TVTX) director Jeffrey Meckler report?
Director Jeffrey Meckler reported exercising stock options for 8,000 shares of Travere common stock at $16.33 per share, then selling 8,000 shares at $45.00 per share in an open‑market transaction conducted on May 4, 2026.
What stock option did Jeffrey Meckler exercise in the Travere (TVTX) Form 4?
Jeffrey Meckler exercised a fully vested stock option covering 8,000 shares of Travere common stock with a $16.33 exercise price. The option was originally granted on May 18, 2016 and had an expiration date of May 18, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
